Early biologic treatment for people with severe ulcerative colitis
Tests early biologic treatment in adults with ulcerative colitis likely to have severe disease.
Key facts
- Who runs it
- Universitetssykehuset Nord-Norge HF
- Where
- Tromsoe, NorwaySee the site
- Trial code
- Registry title
- Debut of Ulcerative Colitis: selective Top-down strategy - the DUCT trial
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 200 people, planned
- Started
- 1 Jan 2025
- Expected to end
- 31 Dec 2031
- Type of study
- Interventional
- Record updated
- 23 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed ulcerative colitis. It tests early biologic treatment in people whose gut tissue tests show a higher chance of severe disease after 1 year.
- Age
- 18 to 65 years
- Sex
- Women and men can join.
- Disease stage
- Ulcerative colitis newly diagnosed, confirmed by colonoscopy and biopsy.
- Earlier treatment
- Cannot be on other biologic medicines at the same time.
- Biomarker or test result
- Positive bio-signature: mucosal TNF transcript ≥ 14100 copies/ug RNA and RHI ≥ 9.
Main reasons for not taking part
- Illness that rules out biologic therapy, such as cancer declared healed less than 5 years ago, tuberculosis, or untreated hepatitis B or C
- Fulminant colitis
- Severe infections such as sepsis, abscesses or opportunistic infections
- Moderate to severe heart failure (NYHA class III/IV)
- Pregnant or planning pregnancy during the study
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Participant must be 18 to 65 years of age inclusive, at the time of signing the informed consent
- Participants who are newly diagnosed with ulcerative colitis (colonscopy and biopsy that confirm the diagnosis)
- Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
- Women with childbearing potential must use highly efficient contraception during and 6 months after the last infliximab administration
Who cannot take part
- Concurrent treatment with other biologic agents, including anakinra and abatacept
- Participants who are required to recive live vaccines during the study period
- Any condition that by standard clinical practice preclude the use of biologic therapy as per local guidelines, including but not exclusive: a. Malignancies declared healed less than 5 years earlier b. Evidence of ongoing or latent tuberculosis according to IGRA test, TB-SPOT or similar local testing practice c. Evidence of ongoing or latent untreated HBV or HCV infection
- Severe infections such as sepsis, abscesses or opportunistic infections
- Moderate to severe heart failure (NYHA class III/IV)
- Alternative diagnosis like C difficile or enteropathogenic infection likely to affect the clinical presentation
- Patients with multiple sclerosis or similar neurological/demyelinating conditions
- Fulminant colitis
- Pregnant or planned pregnancy during the study period
- Participation in other clinical trials or research studies that may interfere with the current study
Where in Norway
- Universitetssykehuset Nord-Norge HFTromsoe, NorwayNot yet recruiting
About the trial
What the trial wants to find out
Debut of Ulcerative Colitis: selective Top-down strategy - the DUCT trial.
Read full original descriptionShow less
This is a proof-of-concept study to evaluate selective top-down treatment algorithm for a subgroup of patients with ulcerative colitis identified as probable severe 1-year outcome by a bio-signature. Positive bio-signature defined as mucosal TNF transcript ≥ 14100 copies/ug RNA and RHI ≥ 9.
Hypothesis: For the most severe cases early biologic therapy (top-down) has a higher chance of achieving deep remission at one year after debut than the regular step-up regimen.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Debut of Ulcerative Colitis: selective Top-down strategy - the DUCT trial
- Plain-language title
- Early biologic treatment for people with severe ulcerative colitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 23 October 2026